Auvelity has not received European Union approval for the treatment of major depressive disorder (MDD). The European Medicines Agency (EMA) declined to approve Auvelity in October 2023, a decision that was later upheld by the EMA's Committee for Medicinal Products for Human Use (CHMP) in January 2024. This means Auvelity is not approved for use in Poland or any other EU member state [1][2].
Why Was Auvelity Not Approved in Europe?
The EMA's decision was based on the assessment that the clinical trial data submitted by the drug's developer did not sufficiently demonstrate a statistically significant improvement in symptoms of MDD. Specifically, the efficacy endpoints in the key trials were not met to the satisfaction of the agency [1][2].
What is Auvelity and How Does it Work?
Auvelity is an oral medication that combines dextromethorphan and bupropion. Dextromethorphan is a cough suppressant that also affects NMDA and sigma-1 receptors in the brain, while bupropion is an antidepressant that inhibits the reuptake of norepinephrine and dopamine. The combination is thought to work by modulating neurotransmitter systems involved in mood regulation [1].
What Were the Key Clinical Trials for Auvelity?
The primary studies supporting Auvelity's development were two Phase 3 trials, ROAMER and METHOD, which evaluated the drug's efficacy in adults with MDD. The FDA approval in the United States was based on these trials, but the EMA found the efficacy data from these studies to be insufficient [1][2].
Can Auvelity Be Purchased in Poland or the EU?
As Auvelity is not approved by the EMA, it cannot be legally marketed or sold in Poland or any other European Union country. Patients in the EU seeking treatment for MDD have access to other approved medications [2].
What Are the Next Steps for Auvelity in Europe?
Following the CHMP's confirmation of the refusal, the developer of Auvelity may have limited recourse for seeking approval in the EU. Further clinical trials or a resubmission with additional data would likely be required, but the path to European approval appears challenging at this time [2].
How Does Auvelity's EU Rejection Compare to its US Approval?
Auvelity received approval from the U.S. Food and Drug Administration (FDA) in January 2023. The FDA's review process and the criteria for approving new drugs can differ from those of the EMA. The efficacy data that led to FDA approval was not deemed sufficient by European regulators [1][2].
What Are Alternative Treatments for Major Depressive Disorder in Europe?
A range of antidepressants are available and approved for use in the EU, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and others. Electroconvulsive therapy (ECT) and psychotherapy are also established treatment options [3].
Where Can I Find More Information on Drug Approvals?
Information on drug approvals and patent information in Europe can be found through regulatory agencies like the European Medicines Agency (EMA) and also through resources that track drug development and market exclusivity, such as DrugPatentWatch.com [4].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.ema.europa.eu/en
[3] https://www.nhs.uk/mental-health/conditions/depression/treatment/
[4] https://drugpatentwatch.com/blog/2023/10/25/auvelity-fails-to-win-eu-approval-for-major-depressive-disorder/